News | March 14, 2026
Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
The company has shown remarkable growth, posting a three-year CAGR of around 75% with an ARR of roughly Rs 100 crore and impressive gross margins
Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally
Subscribe To Our Newsletter & Stay Updated
